Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces it has acted as Financial PR & Investor Relations advisor for the AIM IPO of LungLife AI plc (AIM: “LLAI”), a
developer of clinical diagnostic solutions for the early detection of lung cancer enhanced by artificial intelligence. The team at Walbrook will now manage the Company’s communications with the financial media, research analysts and non-institutional
investors, including new and existing private investors.
On admission, LungLife AI completed a successful placing for gross proceeds of £17 million, with a market capitalisation of approximately £45 million.
LungLife AI is a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence. The Company's diagnostic solutions are designed to make a significant impact in the early detection of lung cancer.
The Company's technology is a combination of the recovery of rare cells and blood-based biomarkers shown to be altered in lung cancer. The Company employs machine learning to improve biomarker detection, and intends to build a deep, novel pool of lung
cancer-related data for AI-enabled applications designed to improve its diagnostic solutions over time.
The Company's core technologies are integrated in the LungLB® test, which is intended to be used as a tool to provide physicians with additional information to help in the decision-making process for people with indeterminate lung nodules that may
be lung cancer following a CT scan. There are estimated to be over 1.5 million individuals with indeterminate lung nodules diagnosed each year in the United States. The LungLB® test may have additional utilities, the most significant of which
is likely to be in monitoring individuals for recurrence following surgical removal of cancerous lung nodules.
Paul McManus, Founder and Managing Director of Walbrook PR, commented: “We are delighted to work with LungLife AI and congratulate the company on their AIM IPO today. LungLife’s proprietary diagnostic technology addresses a significant unmet clinical need for the early detection of lung cancer, which claims more lives than breast, prostate, and colon cancers combined.
“We look forward to developing the Company’s profile with analysts, investors and journalists as they begin this exciting new chapter.”
For more information visit the Company’s website: https://lunglifeai.com/
For further information please contact:
About Walbrook PR:
Walbrook PR was founded in April 2009 by Paul McManus and focuses on providing high quality Financial PR and Investor Relations to Small Cap and AIM listed companies.
Walbrook PR is ranked #2 by number of AIM listed companies with 50 AIM listed clients (Source: AIM Advisers Rankings Guide, October 2021) and ranked #7 by total number of stock market listed clients (Corporate Advisers Rankings Guide, August 2021) advising a total of 58 stock market listed companies across a wide mix of sectors.Walbrook PR prides itself on having a strong reputation for working with growing UK Small Cap and AIM listed companies; a proven IR offering, which focuses on the Private Client Investment Management community and the retail investment community; and on having a proactive, hands-on approach from a committed team with full ownership of the business.